SGLT2-Associated Ketoacidosis: Glucose Can Mislead

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Glycosuria and ketosis may persist after the last dose. Treatment resolution depends on acid–base and ketone recovery, not glucose alone.

SGLT2-Associated Ketoacidosis: Glucose Can Mislead: six-panel learning summary. Full text follows below.
Download infographic (PNG) · Download Markdown · Read text version ·

Text version

Ketones despite modest glucose

SGLT2 inhibition can promote ketogenesis while urinary glucose loss limits hyperglycemia. A reassuring glucose value does not exclude dangerous ketoacidosis.

Recognize the setting

Fasting, surgery, acute illness, reduced insulin delivery, dehydration, and marked carbohydrate restriction increase concern. Type 1 diabetes presents additional risk and regulatory limitations.

Confirm the syndrome

Assess blood ketones, acid–base status, electrolytes, and anion gap. Evaluate other causes of acidosis and identify the precipitating illness.

Treat urgently

Stop the implicated medication and use an appropriate supervised ketoacidosis protocol. Insulin, carbohydrate, fluid, and potassium decisions must follow the patient's evolving physiology.

Plan for prevention

Provide clear illness and procedure instructions, including when to seek help and when medication interruption is required under current guidance.

Avoid false reassurance

Glycosuria and ketosis may persist after the last dose. Treatment resolution depends on acid–base and ketone recovery, not glucose alone.

Continue learning

This graphic summarizes a topic. The full educational pages provide the broader discussion and references.